TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT05004129: Safety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy

Sponsor: AMO Pharma Limited · Phase: PHASE2/PHASE3 · Area: RARE_ORPHAN · Target Enrollment: 76 pts

Competing Trials Overlap

10 Active Trials

Excess Burn Exposure

$3,455,650

Rescue Site Savings

+$2,261,880

Unlock Full NCT05004129 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05004129 Rescue Dossier →